A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)
Phase of Trial: Phase II/III
Latest Information Update: 25 Aug 2015
At a glance
- Drugs Cariprazine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 25 Aug 2015 According to an Allergan media release, pooled data from phase II/III studies will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
- 20 May 2015 Results presented at the 168th Annual Meeting of the American Psychiatric Association.
- 04 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.